COPD – CLI-05993AA3-06

A phase III, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with chronic obstructive pulmonary disease (COPD)

Register Today!

Trial Information

Start DateSeptember 2023
End DateTBD
Trial Duration52 weeks
Number of Visits13
StatusIn Start-up

For additional information
on this trial contact:

Phone705-566-0005